Astellas soars as Xtandi's charge goes on with earlier approval

17 December 2019
astellasuk-big

The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC).

News of this new approval sent shares of Japanese drugmaker Astellas (TSE: 4503) up by 3% in Tuesday’s Tokyo trading, and its collaboration partner Pfizer (NYSE: PFE) opened higher in New York.

In 2019, it is estimated that more than 40,000 men in the USA are living with mCSPC, a form of prostate cancer that has spread to other parts of the body and still responds to a medical or surgical treatment that lowers testosterone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical